| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/01/2011 | WO2011105628A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 09/01/2011 | WO2011105572A1 Novel heteroaryl derivative |
| 09/01/2011 | WO2011105568A1 Dried plant tissue and plant tissue extract for ameliorating central nervous system degenerative diseases accompanied by learning/memory disorders, movement disorders and the like, and pharmaceutical agent and food or beverage each comprising the dried plant tissue and the plant tissue extract |
| 09/01/2011 | WO2011105527A1 Nerve growth promoter |
| 09/01/2011 | WO2011105435A1 Therapeutic agent for eating disorders |
| 09/01/2011 | WO2011105099A1 Compound containing a novel 4-alkoxypyridine formation and medicine containing same |
| 09/01/2011 | WO2011104338A1 Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| 09/01/2011 | WO2011104337A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | WO2011104334A1 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions |
| 09/01/2011 | WO2011104298A1 Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids |
| 09/01/2011 | WO2011103718A1 Controlled (sustained) release preparation containing quetiapine and preparation method and use thereof |
| 09/01/2011 | WO2011103715A1 Task channel antagonists |
| 09/01/2011 | WO2011103667A1 Agonistic antibodies to trkb receptors and uses thereof |
| 09/01/2011 | WO2011070177A3 Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
| 09/01/2011 | WO2011052888A3 (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases |
| 09/01/2011 | WO2011007136A3 Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein |
| 09/01/2011 | WO2010132352A3 Spiro compounds and their use as therapeutic agents |
| 09/01/2011 | US20110213193 Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier |
| 09/01/2011 | US20110213034 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same |
| 09/01/2011 | US20110213029 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands |
| 09/01/2011 | US20110213028 Fatty acid mycophenolate derivatives and their uses |
| 09/01/2011 | US20110213021 Compositions and methods for treating nos-associated diseases |
| 09/01/2011 | US20110213017 Targeted delivery of glycine receptors to excitable cells |
| 09/01/2011 | US20110213010 Methods and compositions for the treatment of huntington's disease |
| 09/01/2011 | US20110213002 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 09/01/2011 | US20110213001 Pharmaceutical compositions |
| 09/01/2011 | US20110212999 Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| 09/01/2011 | US20110212997 Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 09/01/2011 | US20110212992 Novel p2x7r antagonists and their use |
| 09/01/2011 | US20110212989 Therapeutic methods and compositions involving isoflavones |
| 09/01/2011 | US20110212987 Method of reducing cns and gastrointestinal side affects associated with long-term dextromethorphan/low-dose quinidine combination therapy |
| 09/01/2011 | US20110212985 Naltrexone Long Acting Formulations and Methods of Use |
| 09/01/2011 | US20110212980 Combinations for the treatment of migraine |
| 09/01/2011 | US20110212976 Deuterium-enriched risperidone |
| 09/01/2011 | US20110212970 Compounds that modulate intracellular calcium |
| 09/01/2011 | US20110212968 Phenethylamide derivatives and their heterocyclic analogues |
| 09/01/2011 | US20110212963 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 09/01/2011 | US20110212960 New compounds for the treatment of cns disorder |
| 09/01/2011 | US20110212957 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| 09/01/2011 | US20110212956 Pyrazolopyrimidines for treating CNS disorders |
| 09/01/2011 | US20110212952 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (vri) activity |
| 09/01/2011 | US20110212947 Substituted indole compounds having nos inhibitory activity |
| 09/01/2011 | US20110212946 Quinolone Neuropeptide S Receptor Antagonists |
| 09/01/2011 | US20110212944 2-oxo-1-pyrrolidine derivatives |
| 09/01/2011 | US20110212943 Novel bridged cyclic compounds as histone deacetylase inhibitors |
| 09/01/2011 | US20110212942 Inhibitors of polo-like kinase |
| 09/01/2011 | US20110212941 Imidazoisoindole Neuropeptide S Receptor Antagonists |
| 09/01/2011 | US20110212940 S1P Receptor Modulating Compounds and Use Thereof |
| 09/01/2011 | US20110212937 Compounds for the reduction of beta-amyloid production |
| 09/01/2011 | US20110212928 Methods and compositions for improving cognitive function |
| 09/01/2011 | US20110212927 Carbonate prodrugs and methods of using the same |
| 09/01/2011 | US20110212926 Water-soluble acetaminophen analogs |
| 09/01/2011 | US20110212925 Novel compounds as receptor modulators with therapeutic utility |
| 09/01/2011 | US20110212923 Phosphate Derivatives of Substituted Benzoxazoles |
| 09/01/2011 | US20110212920 N-Substituted Benzene Sulfonamides |
| 09/01/2011 | US20110212919 Protein cross-linking inhibitor |
| 09/01/2011 | US20110212917 Agent for ameliorating brain hypofunction |
| 09/01/2011 | US20110212914 Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them |
| 09/01/2011 | US20110212904 Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug |
| 09/01/2011 | US20110212903 Metal-binding compounds and uses therefor |
| 09/01/2011 | US20110212896 Peptides for the treatment of oxidative stress related disorders |
| 09/01/2011 | US20110212895 Treatment of Cognitive and Learning Impairment |
| 09/01/2011 | US20110212890 Metastin derivative and use thereof |
| 09/01/2011 | US20110212888 Diet and methods for improving learning capacity, mood and behavior in mammals |
| 09/01/2011 | US20110212883 Radical scavenger and active oxygen eliminating agent |
| 09/01/2011 | US20110212882 Uses of kappa opioid synthetic peptide amides |
| 09/01/2011 | US20110212191 Composition for the maintenance of blood sugar levels comprising cinnamon and ginseng |
| 09/01/2011 | US20110212188 Preventing and/or treating cardiovascular disease and/or associated heart failure |
| 09/01/2011 | US20110212183 Antioxidant composition for marine oils comprising tocopherol, rosemary extract, ascorbic acid and green tea extract |
| 09/01/2011 | US20110212174 Controlled release arginine formulations |
| 09/01/2011 | US20110212173 Controlled Release Treatment of Depression |
| 09/01/2011 | US20110212166 Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses |
| 09/01/2011 | US20110212141 Injectable depot formulation comprising crystals of iloperidone |
| 09/01/2011 | US20110212136 Nanosphere/Microsphere Delivery System for the Treatment of Spinal Cord Injury |
| 09/01/2011 | US20110212122 Nerve Growth Factor Conjugates and Uses Thereof |
| 09/01/2011 | US20110212109 Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES |
| 09/01/2011 | US20110212103 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| 09/01/2011 | US20110212102 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | US20110212099 Methods of modulating il-22 and il-17 |
| 09/01/2011 | US20110212097 Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases |
| 09/01/2011 | US20110212094 Dual variable domain immunoglobulins and uses thereof |
| 09/01/2011 | US20110212087 Antibody Fc Mutants with Ablated Effector Functions |
| 09/01/2011 | US20110212079 Adaptive biochemical signatures |
| 09/01/2011 | US20110212075 Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders |
| 09/01/2011 | US20110212072 Inhibitors of Fatty Acid Oxidation for Prophylaxis and Treatment of Diseases Related to Mitochondrial Dysfunction |
| 09/01/2011 | US20110212070 Methods of differentiating and protecting cells by modulating the p38/mef2 pathway |
| 09/01/2011 | US20110212069 Modulation of Microglia Activation |
| 09/01/2011 | US20110212066 Method of fostering the restoration of a body function using cells of the root sheath, composition and preparation method |
| 09/01/2011 | US20110212060 Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases |
| 09/01/2011 | US20110212055 Neurodegenerative disorders |
| 09/01/2011 | US20110212053 Phosphatidylinositol 3 kinase inhibitors |
| 09/01/2011 | US20110212051 Variants of vascular endothelial growth factor (vegf) receptor and use thereof |
| 09/01/2011 | US20110212034 Sublingual Buccal Effervescent |
| 09/01/2011 | US20110212031 Novel substituted azabenzoxazoles |
| 09/01/2011 | US20110212026 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system |
| 09/01/2011 | CA2791166A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 09/01/2011 | CA2791105A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | CA2791103A1 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3-d] pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions |
| 09/01/2011 | CA2790996A1 Therapeutic agent for eating disorders |
| 09/01/2011 | CA2790820A1 Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |